Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

BACKGROUND: Targeted agents, such as antiangiogenic drugs (e.g., bevacizumab) and poly(ADP-ribose) polymerase inhibitors (e.g., rucaparib), have been shown to improve outcomes in patients with newly diagnosed or recurrent ovarian cancer. Evidence suggests that combinations of these two classes of ta...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Target Oncol
Huvudupphovsmän: Lorusso, Domenica, Maltese, Giuseppa, Sabatucci, Ilaria, Cresta, Sara, Matteo, Cristina, Ceruti, Tommaso, D’Incalci, Maurizio, Zucchetti, Massimo, Raspagliesi, Francesco, Sonetto, Cristina, Sinno, Valentina, Ronzulli, Dominique, Giolitto, Serena, de Braud, Filippo
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer International Publishing 2020
Ämnen:
Original Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810645/
https://ncbi.nlm.nih.gov/pubmed/33369704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00780-4
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk